INTRODUCTION
============

Benzodiazepines are among the most commonly prescribed sedative-hypnotics and are highly prevalent (\>10%) in elderly patients \[[@b1-pi-2019-0275],[@b2-pi-2019-0275]\]. However, many observational studies raised safety concerns over benzodiazepine use and the potential risk of dementia \[[@b3-pi-2019-0275]-[@b5-pi-2019-0275]\]. Though the mechanism of the influence of benzodiazepine on the development of dementia is uncertain, there are hypotheses that, based on the neural compensation and cognitive reserve concepts, benzodiazepine users may utilize undamaged alternative neural networks to reduce cognitive disorders \[[@b6-pi-2019-0275]\]. However, by reducing the brain activation level, benzodiazepines could impair this ability and increase the potential risk of dementia. Susceptibility to benzodiazepine-induced dementia may differ across sex \[[@b7-pi-2019-0275]\], age groups \[[@b8-pi-2019-0275]\], and the use of multiple medications \[[@b9-pi-2019-0275]\]. Moreover, heterogeneity has been observed in individual safety profiles of benzodiazepine components \[[@b10-pi-2019-0275]\].

A meta-analysis, integrating four cohort studies and six case-control studies, reported that benzodiazepine users had a 78% higher potential risk of dementia compared to non-users \[[@b11-pi-2019-0275]\]. A subsequent signal detection study using the US Food and Drug Administration Adverse Event Reporting System Database and the Canada Vigilance Adverse Reaction Online Database reported a 1.63-fold and 1.88-fold increased association between benzodiazepine and dementia, respectively \[[@b10-pi-2019-0275]\]. However, a prospective study found no significant differences in the cognitive performance between benzodiazepine users and non-users \[[@b12-pi-2019-0275]\].

The safety of benzodiazepines has remained uncertain due to the inconsistent results of previous studies and the unknown mechanisms by which benzodiazepine may influence dementia. The case/non-case method, derived from the case-control study design used in epidemiology studies, is a pharmacovigilance method validated for signal detection \[[@b13-pi-2019-0275]\]. Although a previous case/non-case study reported an association between benzodiazepine use and memory disorders \[[@b14-pi-2019-0275]\], selection bias may have undermined its results. All reports, except memory disorder cases, were selected as non-cases without balancing important demographic features. Our objective was to generate a reliable signal of the association between benzodiazepine use and the potential risk of cognitive impairment or dementia. We aimed to identify susceptible subgroups using a case/non-case method while controlling for the confounding of age and sex.

METHODS
=======

Data source
-----------

Reported cases related to cognitive impairment or dementia were mined using Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database (KIDS-KD) \[[@b15-pi-2019-0275]\]. KIDS-KD consists of 9 tables: basic information, drug information, ADR information, critical case information, reporter information, causality assessment information, disease history of ADR information, group information, and completeness information. Of 1,089,163 reports accumulated in KIDS-KD between December 1988 and June 2016, 212,127 reports related to benzodiazepine and other medications (opioid analgesics and antidepressants) were identified after excluding cases without age or sex and those younger than 40 years of age ([Figure 1](#f1-pi-2019-0275){ref-type="fig"}). This study was approved by the institutional review board of Sungkyunkwan University (No. 2017-08-008-001), which waived the informed consent, as only deidentified data were used in this study.

Case/non-case approach
----------------------

The case/non-case approach measures the disproportionality of combinations between a drug and a particular ADR in a pharmacovigilance database \[[@b15-pi-2019-0275]-[@b18-pi-2019-0275]\]. This approach was chosen to assess the disproportionality of reports for cognitive impairment or dementia associated with benzodiazepines compared to opioid analgesics or antidepressants. Reporting odds ratio (ROR) was calculated as the odds of the exposure to benzodiazepines in comparison with that to other drugs (opioid analgesics, and antidepressants) in cases divided by the odds of the exposure to benzodiazepines in non-cases ([Figure 2](#f2-pi-2019-0275){ref-type="fig"}).

To minimize data duplication, we eliminated reports whose report number, generic name, preferred terms (PTs) and included terms (ITs) according to World Health Organization Adverse Reactions Terminology (WHO-ART) that were duplicated. Each case, defined as a report of cognitive impairment or dementia, was matched to 10 non-cases by age and sex to minimize confounding from these variables. Cognitive impairment or dementia cases were defined using PTs and ITs of the four-level hierarchical system structure of WHOART (adverse reaction record number: "0100," "0199," "1453," and "1877"; [Supplementary Table 1](#SD1-pi-2019-0275){ref-type="supplementary-material"} in the online-only Data Supplement). Benzodiazepines were classified as short-, intermediate-, and long-acting according to half-lives; short-acting \<12 hours; intermediate-acting 12--23 hours; long-acting ≥24 \[[@b19-pi-2019-0275],[@b20-pi-2019-0275]\].

Causality assessment
--------------------

In South Korea, the causality of each adverse event (AE) report from healthcare professionals is evaluated using the modified algorithm based on the Naranjo algorithm developed by WHO-UMC \[[@b21-pi-2019-0275]\]. Using this algorithm, healthcare professionals including doctors, pharmacists, nurses, and pharmaceutical companies assess causality between drugs and AEs. The evidence level is categorized into six groups: certain, probable/likely, possible, unlikely, conditional/unclassified, and unassessable. The items of the causality assessment algorithm include the time order between treatment and AEs, outcomes when the drugs were discontinued or re-administered, history of a similar reaction to the same or similar drugs in any previous exposure, concomitant drug use, presence of alternative causes of the reaction, and the presence of already known information on the AEs, based on the product labels or previous case reports.

Potential confounders
---------------------

Potential covariates for the association between benzodiazepine use and cognitive impairment or dementia were categorized as age group, sex, year of reporting, polypharmacy, and comorbidities. Polypharmacy was defined as a concomitant prescription of ≥5 drugs \[[@b22-pi-2019-0275]\]. Comorbidities were coded using the 6th and 7th Korean Standard Classification of Diseases (KCD) and included the following: renal failure, high blood pressure, paranoid schizophrenia, urinary incontinence, constipation, other cholelithiasis, lower back pain, history of major surgery, atrial fibrillation and flutter, bronchopneumonia, normal-pressure hydrocephalus, rheumatoid arthritis, hyperplasia of the prostate, malignant neoplasm of the bronchus or lung, cough, history of malignant neoplasm of digestive organs, complex partial seizures developing into secondarily generalized seizures, migraines, atypical schizophrenia, other cerebrovascular diseases, other and unspecified abdominal pain, dysuria, restlessness and agitation, hepatoma, multiple myeloma, unspecified hypertension, spinal stenosis, and headaches.

Additionally, reporting groups were assessed to judge the reliability of the reports. Reporting groups by profession were comprised of doctors, pharmacists, nurses, and consumers, based on information provided about the occupation of the person who made the report of the AEs. Reporting groups by affiliation consisted of hospitals/clinics, pharmacies, manufacturers, and consumers.

Statistical analysis
--------------------

Cases of benzodiazepine use, and comparator drug use were compared to determine whether benzodiazepine increases the signal of cognitive impairment or dementia. Logistic regression analysis was conducted to estimate RORs and 95% confidence intervals (CIs). The models were adjusted for age, sex, year of reporting, polypharmacy, and comorbidities.

Subgroup analysis was performed according to age group, sex, and polypharmacy. Sensitivity analyses were conducted to assess bias in the causality of reports. Reports with causality assessments of "certain," "probable," and "possible" were analyzed and the total number of cases was readjusted to 249,640, with 243 cognitive impairment or dementia cases and 249,397 non-cases. After 1:10 matching, 243 cases, and 2,430 non-cases were included. All statistical procedures were performed using the SAS 9.4 software (SAS Institute Inc., Cary, NC, USA). A two-tailed value of p\<0.05 indicated statistical significance.

RESULTS
=======

From January 2007 to December 2016, there were 1,086,584 AE-pairs pairs involving benzodiazepines that were identified. A total of 776,331 AE-pairs were included after excluding cases without age or sex (n=162,677) and those younger than 40 years of age (n=147,576). There were 887 cognitive impairment or dementia AE-pairs defined as cases, and 775,444 other AE-pairs were defined as non-cases. After 1:10 matching according to age and sex, 887 cases and 8,870 non-cases were included.

[Table 1](#t1-pi-2019-0275){ref-type="table"} shows the characteristics of cases and non-cases; 75.9% and 87.9% of cognitive impairment or dementia cases and matched non-cases, respectively, were reported by healthcare professionals. Among the cases, disproportionality was found after any use of benzodiazepine as compared with nonuse. There was a difference in the magnitude of association before matching (adjusted ROR, aROR=2.04; 95% CI=1.55-- 2.68) and after matching (aROR=2.23; 95% CI=1.61--3.09). Sensitivity analysis was implemented to limit AEs to those with certain, probable, or possible causality assessments; this restriction increased the disproportionality of benzodiazepine use (aROR=2.69; 95% CI=1.66--4.38) compared to that observed across all AEs ([Table 2](#t2-pi-2019-0275){ref-type="table"}). Individual benzodiazepine drugs had heterogeneous levels of safety profiles for cognitive impairment or dementia ([Table 3](#t3-pi-2019-0275){ref-type="table"}).

In the subgroup analysis ([Table 4](#t4-pi-2019-0275){ref-type="table"}), there was no significant difference in RORs among different age groups. Higher ROR estimates were observed in female (aROR=2.33, 95% CI=1.48--3.67) than in male (aROR=1.89, 95% CI=1.11--3.20), and in those with polypharmacy (aROR=2.20, 95% CI=1.35--3.57) than in those without polypharmacy (aROR=2.06, 95% CI=1.30--3.27). However, the subgroup difference was not statistically significant in the interaction test.

DISCUSSION
==========

This case/non-case study using 10 years of spontaneous nationwide reports showed that benzodiazepine use was associated with a potential risk of cognitive impairment or dementia. Among the subgroups, higher RORs were observed in female and those who had polypharmacy. The possible association was supported by the disproportionality analysis, in which the magnitude of ROR increased when the analysis was restricted to reports suspected to have associations in the causality assessment by healthcare professionals. Benzodiazepine use was associated with a 2.69-fold increased report of cognitive impairment or dementia when assessed using reports with certain, probable, and/or possible in causality assessments. Heterogeneity was observed in the individual safety profile of benzodiazepine components.

Despite being statistically insignificant, higher ROR estimates for cognitive decline/dementia in females and those with polypharmacy suggest that these subgroups are more susceptible to benzodiazepine-associated dementia risk. Similar findings that support our results are in a previously reported systematic review which showed a higher association between benzodiazepine use and dementia among females (Odds ratio=1.16, 95% CI=1.00--1.36) than in males (1.00, 0.96--1.04) \[[@b11-pi-2019-0275]\]. Patients with polypharmacy have a particularly increased risk of benzodiazepine-induced cognitive impairment because benzodiazepines may trigger drug--drug interactions when concomitantly used with other drugs metabolized by CYP3A \[[@b23-pi-2019-0275]\].

There was no difference in ROR estimates among different age groups. This can be due to the depletion of susceptible effects in older patients \[[@b24-pi-2019-0275]\], in which these patients already at a high risk of dementia from other events associated with dementia such as neurological and psychiatric disorders, leading to a non-differential ROR compared to younger groups. We observed a heterogeneity in the risk of individual benzodiazepine drugs, in contrast to the findings from the US FAERS database where the ROR values increased with the duration of benzodiazepine action. This inconsistency may be due to the discrepancies in baseline characteristics among the users of different benzodiazepine components in our database or the difference in clinical indications.

Although the mechanism of the influence of benzodiazepine on dementia is unknown, the following hypotheses support our results. First, benzodiazepine has neuro-sedative effects and causes cognitive deficits, which may lead to a decrease in cognitive reserve when used chronically \[[@b25-pi-2019-0275],[@b26-pi-2019-0275]\]. Second, chronic use of benzodiazepines could exacerbate dementia by downregulating gamma-aminobutyric acid (GABA) receptors \[[@b27-pi-2019-0275],[@b28-pi-2019-0275]\]. Finally, benzodiazepine use may increase the potential risk of cognitive impairment in early dementia because of the GABA-secreting activity expressed in amyloid plaques \[[@b29-pi-2019-0275]\].

Our observations are in line with previous pharmacoepidemiologic studies reporting increasing potential risks among benzodiazepine users \[[@b3-pi-2019-0275]-[@b5-pi-2019-0275],[@b30-pi-2019-0275],[@b31-pi-2019-0275]\]. The results are also consistent with those of a signal detection study conducted in Japan on the association between benzodiazepine use and the potential risk of dementia \[[@b10-pi-2019-0275]\]. A previous case/non-case study showed a greater association than did our study, reporting a more than 6-fold increased reports of memory disorder among benzodiazepine users \[[@b14-pi-2019-0275]\]. Contrary to this, some cohort studies observed no association between benzodiazepine use and dementia \[[@b32-pi-2019-0275],[@b33-pi-2019-0275]\].

Our results are subject to reverse causation owing to the limitations of the AE reporting system database, which lacks information on the presence of biologically plausible lag time between benzodiazepine initiation and the occurrence of dementia to consider disease latency. Provided that dementia has a latent period of several years and insidious onset, it is possible that benzodiazepines were prescribed for prodromal symptoms of dementia. However, given that over 75% of cognitive impairment or dementia reports were from healthcare professionals in our database and the magnitude of ROR increased when the analysis was restricted to reports suspected to have association in the causality assessment, our signal indicates a possible association between benzodiazepine and the risk of cognitive impairment or dementia.

Our study has several strengths. We used a nationwide spontaneous reporting database, which accumulated 1,086,564 AE reports over 10 years. Second, the case/non-case design has an advantage in the feasibility of using demographic and clinical variables in the analyses, which has been a limitation of traditional signal detection methods, such as proportional reporting ratios, RORs, and information components. Since increasing age and female sex are known risk factors for dementia, cases and non-cases were matched on these factors to exclude potential confounding. Matching is the most effective technique to increase comparability between cases and non-cases because it ensures equal distributions of matching variables. We also performed multivariate analyses to control other confounders. Given that benzodiazepines are one of the most commonly used psychotropic drugs in elderly patients, our findings have important public health implications for this population.

However, our study should be interpreted with caution. First, the limitations of spontaneous reporting may limit causal interpretation of our findings, as such reports are subject to the subjective judgments of the reporter. Second, our results are subject to protopathic bias and may have been influence by uncontrolled confounders as the database lacks clinical or demographic information. Important epidemiologic factors associated with dementia, such as depression, low education level, and smoking were not controlled in the analyses \[[@b34-pi-2019-0275]\]. Our analyses also did not reflect the influence of alcohol consumption, which reportedly increases the potential risk of cognitive impairment 3.6-fold \[[@b1-pi-2019-0275]\], or body mass index (BMI). Obese patients (BMI \>30) had a 74% increased risk of dementia compared to those with average weight \[[@b35-pi-2019-0275]\]. Third, the imbalances of baseline characteristics between cases and non-cases may lead to the ROR overestimations for benzodiazepine use and dementia. For example, the higher prevalence of paranoid schizophrenia among cases in which benzodiazepine may be used for the treatment may lead to a higher benzodiazepine prevalence and consequent ROR overestimation \[[@b36-pi-2019-0275]\]. Although we adjusted the comorbidities in the outcome model, the imbalance of confounders between cases and non-cases may have resulted in ROR overestimations. Cognitive decline and dementia can be clinically different conditions. The difference between these two conditions lies in whether the patient has impaired activities of daily living \[[@b37-pi-2019-0275]\]. Due to the inherent limitations of a retrospective study, it remains unclear how the clinical judgement differentiated cognitive decline from dementia. Nonetheless, we used both cognitive decline and dementia to define a case since these two conditions share common symptoms. Further, cognitive impairment can be a prodromal stage of dementia \[[@b38-pi-2019-0275]\].

In conclusion, our case/non-case study detected an increased association for cognitive impairment or dementia in female and in those with polypharmacy associated with benzodiazepine use from a 10-year, cumulated AE database. We found inconsistencies in dementia safety profiles across benzodiazepine components, which warrant further investigations. South Korea has a rapidly aging population, which is a non-modifiable potential risk factor for dementia \[[@b39-pi-2019-0275]\]. In this regard, the high prevalence of benzodiazepine use and its potential association with dementia are an important public health concern. We recommend further pharmacoepidemiologic studies to confirm our findings.
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###### 

Characteristics of the cases (cognitive impairment or dementia) and non-cases (non-dementia) matched by factors from KIDS-KD, 2007--2016

  Characteristics                  Before matching                 After matching on age and sex (1:10)                                                          
  -------------------------------- ------------------------------- -------------------------------------- ---------------- --------- ------------ -------------- ---------
  Age group                                                                                               \<0.001                                 1.00           
                                   40--44                          54 (6.1)                               60,596 (7.8)               54 (6.1)     540 (6.1)      
                                   45--49                          48 (5.4)                               83,930 (10.8)              48 (5.4)     480 (5.4)      
                                   50--54                          26 (2.9)                               120,610 (15.6)             26 (2.9)     260 (2.9)      
                                   55--59                          133 (15.0)                             104,767 (13.5)             133 (15.0)   1,330 (15.0)   
                                   60--64                          171 (19.3)                             96,275 (12.4)              171 (19.3)   1,710 (19.3)   
                                   65--69                          103 (11.6)                             105,472 (13.6)             103 (11.6)   1,030 (11.6)   
                                   70--74                          87 (9.8)                               98,039 (12.6)              87 (9.8)     870 (8.8)      
                                   75--79                          174 (19.6)                             63,566 (8.2)               174 (19.6)   1,740 (19.6)   
                                   80--84                          28 (3.2)                               31,716 (4.1)               28 (3.2)     280 (3.2)      
                                   ≥85                             63 (7.1)                               10,473 (1.4)               63 (7.1)     630 (7.1)      
  Sex                                                                                                     \<0.078                                 1.00           
                                   Male                            417 (47.0)                             341,503 (44.0)             417 (47.0)   4,170 (47.0)   
                                   Female                          470 (53.0)                             433,941 (56.0)             470 (53.0)   4,700 (53.0)   
  Reporting group by profession                                                                           \<0.001                                 \<0.001        
                                   Doctor                          465 (52.4)                             389,733 (50.3)             465 (52.4)   4,814 (54.3)   
                                   Pharmacist                      81 (9.1)                               57,138 (7.4)               81 (9.1)     646 (7.3)      
                                   Nurse                           78 (8.8)                               155,761 (20.1)             78 (8.8)     1,781 (20.1)   
                                   Consumer                        12 (1.4)                               5,211 (0.7)                12 (1.4)     63 (0.7)       
                                   Other healthcare professional   49 (5.5)                               45,446 (5.9)               49 (5.5)     555 (6.3)      
  Reporting group by affiliation                                                                          \<0.001                                 \<0.001        
                                   Hospitals/clinics               254 (28.6)                             313,700 (40.5)             254 (28.6)   3,628 (40.9)   
                                   Pharmacies                      10 (1.1)                               13,389 (1.7)               10 (1.1)     134 (1.5)      
                                   Manufacturers                   621 (70.0)                             447,112 (57.7)             621 (70.0)   5,096 (57.5)   
                                   Consumers                       2 (0.2)                                850 (0.1)                  2 (0.2)      7 (0.1)        
                                   Others                          0 (0.0)                                393 (0.1)                  0 (0.0)      5 (0.1)        
  Polypharmacy (≥5)                                                                                       \<0.078                                 \<0.190        
                                   Yes                             665 (75.0)                             560,564 (72.3)             665 (75.0)   6465 (72.9)    
                                   No                              222 (25.0)                             214,880 (27.7)             222 (25.0)   2405 (27.1)    
  Comorbidities                                                                                                                                                  
                                   Renal failure                   69 (7.8)                               1,690 (0.2)      \<0.001   69 (7.8)     23 (0.3)       \<0.001
                                   Hypertension                    53 (6.0)                               8,028 (1.0)      \<0.001   53 (6.0)     90 (1.0)       \<0.001
                                   Paranoid Schizophrenia          38 (4.3)                               528 (0.1)        \<0.001   38 (4.3)     6 (0.1)        \<0.001
                                   Urinary incontinence            35 (3.9)                               561 (0.1)        \<0.001   35 (3.9)     7 (0.1)        \<0.001
                                   Constipation                    29 (3.3)                               2,044 (0.3)      \<0.001   29 (3.3)     22 (0.2)       \<0.001
                                   Other cholelithiasis            29 (3.3)                               1,339 (0.2)      \<0.001   29 (3.3)     33 (0.4)       \<0.001
                                   Low back pain                   21 (2.4)                               2,022 (0.3)      \<0.001   21 (2.4)     221 (2.5)      \<0.821
                                   History of major surgery        21 (2.4)                               10,572 (1.4)     \<0.010   21 (2.4)     306 (3.4)      \<0.088
                                   AFF                             14 (1.6)                               109 (0.0)        \<0.001   14 (1.6)     1 (0.0)        \<0.001
                                   Bronchopneumonia                14 (1.6)                               57 (0.0)         \<0.001   14 (1.6)     3 (0.0)        \<0.001
                                   NPH                             13 (1.5)                               35 (0.0)         \<0.001   13 (1.5)     1 (0.0)        \<0.001
                                   RA                              12 (1.4)                               1,059 (0.1)      \<0.001   12 (1.4)     17 (0.2)       \<0.001
                                   Hyperplasia of prostate         12 (1.4)                               7,214 (0.9)      \<0.190   12 (1.4)     74 (0.8)       \<0.115
                                   Lung cancer                     11 (1.2)                               4,891 (0.6)      \<0.022   11 (1.2)     54 (0.6)       \<0.028
                                   Cough                           10 (1.1)                               1,059 (0.1)      \<0.001   10 (1.1)     11 (0.1)       \<0.001
  Year of reporting                                                                                       \<0.002                                 \<0.093        
                                   2007                            28 (3.2)                               50,401 (6.5)               28 (3.2)     206 (2.3)      
                                   2008                            16 (1.8)                               8,821 (1.1)                16 (1.8)     111 (1.3)      
                                   2009                            35 (3.9)                               12,410 (1.6)               35 (3.9)     150 (1.7)      
                                   2010                            107 (12.1)                             35,558 (4.6)               107 (12.1)   378 (4.3)      
                                   2011                            35 (3.9)                               37,978 (4.9)               35 (3.9)     452 (5.1)      
                                   2012                            17 (1.9)                               53,666 (6.9)               17 (1.9)     622 (7.0)      
                                   2013                            129 (14.5)                             180,911 (23.3)             129 (14.5)   1,891 (21.3)   
                                   2014                            23 (2.6)                               46,587 (6.0)               23 (2.6)     537 (6.1)      
                                   2015                            155 (17.5)                             171,127 (22.1)             155 (17.5)   2,239 (25.2)   
                                   2016                            342 (38.6)                             177,985 (23.0)             342 (38.6)   2,284 (25.7)   

KIDS-KD: Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database, AFF: atrial fibrillation and flutter, NPH: normal pressure hydrocephalus, RA: rheumatoid arthritis

###### 

Disproportionality analysis of cognitive impairment or dementia associated with the use of benzodiazepines in all adverse events and applied to reports with certain, probable, and possible causality assessments from KIDS-KD, 2007--2016

                                                                                               Before matching   After matching on age and sex (1:10)                                                                         
  -------------------------------------------------------------------------------------------- ----------------- -------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Including all causality assessments                                                                                                                                                                                         
                                                                                               Benzodiazepine    1.98                                   1.51   2.59   2.04   1.55   2.68   2.00   1.49   2.69   2.23   1.61   3.09
  Restricted to adverse events with causality recorded as certain, probable, and/or possible                                                                                                                                  
                                                                                               Benzodiazepine    2.85                                   1.87   4.35   2.70   1.76   4.12   2.58   1.62   4.12   2.69   1.66   4.38

adjusted according to age group, sex, year of reporting, polypharmacy, and comorbidity.

KIDS-KD: Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database, ROR: reporting odds ratio, 95% CI: 95% confidence interval

###### 

Disproportionality analysis of cognitive impairment or dementia associated with the use of individual benzodiazepines from KIDS-KD, 2007--2016^[\*](#tfn2-pi-2019-0275){ref-type="table-fn"}^

                                        Before matching   After matching on age and sex (1:10)                                                                            
  ------------------------------------- ----------------- -------------------------------------- ------ ------- ------ ------ ------- ------ ------ ------- ------ ------ -------
  Short-acting benzodiazepines                                                                                                                                            
                                        Etizolam          1.36                                   0.42   4.36    1.55   0.48   5.03    1.20   0.33   4.36    1.26   0.28   5.64
                                        Midazolam         0.49                                   0.21   1.15    0.44   0.18   1.05    0.46   0.19   1.12    0.36   0.13   1.00
                                        Tofisopam         1.59                                   0.22   11.54   1.53   0.20   11.44   0.73   0.09   6.07    0.76   0.08   7.33
                                        Triazolam         0.77                                   0.19   3.15    0.73   0.17   3.03    0.86   0.19   3.93    0.77   0.15   4.04
  Intermediate-acting benzodiazepines                                                                                                                                     
                                        Alprazolam        1.13                                   0.60   2.14    1.23   0.64   2.36    1.24   0.61   2.52    1.72   0.75   3.97
                                        Bromazepam        3.31                                   0.46   24.05   3.16   0.42   23.91   2.61   0.23   29.28   1.56   0.12   20.17
                                        Flunitrazepam     8.75                                   2.11   36.31   7.32   1.64   32.58   2.64   0.47   14.77   1.38   0.15   12.53
                                        Lorazepam         1.53                                   0.88   2.67    1.64   0.93   2.90    1.92   1.03   3.57    1.67   0.81   3.43
  Long-acting benzodiazepines                                                                                                                                             
                                        Clonazepam        0.81                                   0.32   2.03    0.71   0.28   1.79    0.61   0.23   1.62    0.72   0.24   2.16
                                        Diazepam          0.79                                   0.32   1.98    0.80   0.32   2.02    0.88   0.33   2.38    1.05   0.32   3.43

analysis based on logistic on analysis, reference group: other benzodiazepines. This table displays only benzodiazepines referenced in over 100 reports,

adjusted according to age group, sex, year of reporting, and polypharmacy.

KIDS-KD: Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database, ROR: reporting odds ratio, 95% CI: 95% confidence interval

###### 

Subgroup analysis associated with factors for cognitive impairment or dementia: age (resetting for higher causality on cognitive impairment or dementia), sex, and polypharmacy from KIDS-KD, 2007--2016

                                                               Before matching   After matching on age and sex (1:10)                                                                         
  ------------------------------------------------------------ ----------------- -------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Age group^[\*](#tfn4-pi-2019-0275){ref-type="table-fn"}^                                                                                                                                    
                                                               ≤64               2.13                                   1.47   3.09   1.80   1.21   2.68   1.92   1.28   2.87   2.37   1.46   3.84
                                                               65--74            1.77                                   0.94   3.35   1.69   0.88   3.25   2.19   1.09   4.41   2.22   1.04   4.75
                                                               ≥75               1.80                                   1.08   2.98   2.24   1.32   3.82   2.06   1.19   3.59   2.33   1.22   4.44
  Sex^[†](#tfn5-pi-2019-0275){ref-type="table-fn"}^                                                                                                                                           
                                                               Male              1.88                                   1.24   2.84   1.51   0.96   2.38   1.78   1.14   2.79   1.89   1.11   3.20
                                                               Female            2.07                                   1.44   2.96   2.15   1.48   3.11   2.20   1.49   3.26   2.33   1.48   3.67
  Polypharmacy^[‡](#tfn6-pi-2019-0275){ref-type="table-fn"}^                                                                                                                                  
                                                               Yes               1.67                                   1.17   2.40   1.57   1.08   2.29   1.95   1.32   2.89   2.20   1.35   3.57
                                                               No                2.69                                   1.77   4.08   2.47   1.62   3.75   2.20   1.40   3.46   2.06   1.30   3.27

adjusted for sex, polypharmacy, and comorbidity,

adjusted for age group, polypharmacy, and comorbidity,

adjusted for age group, sex, and comorbidity.

KIDS-KD: Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database, ROR: reporting odds ratio, 95% CI: 95% confidence interval

[^1]: These authors contributed equally to this work.
